EpicentRx, Inc, a California-based clinical-stage biopharmaceutical company, announced on Friday that data from a phase two randomised clinical trial of RRx-001 compared to regorafenib in subjects with third/fourth line colorectal cancer was chosen for a presentation at the 2023 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held from January 19 to January 21 in San Francisco.

The phase two study is called ROCKET and compares the safety and efficacy of RRx-001 and irinotecan compared to regorafenib in 34 subjects with third/fourth line colorectal cancer that were earlier treated with irinotecan-based therapy.

Positive results from the completed Phase 2 study demonstrate improved overall survival and significantly improved progression free survival of RRx-001 plus irinotecan compared with regorafenib in 3rd/4th line colorectal cancer. ROCKET was carried out in collaboration with Dr George Fisher from Stanford and Dr Keola Beale from Kaiser Permanente Moanalua Medical Center.